Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Credit agrmnt [a] Appointed director Monthly oper. report
|
ACCENTIA BIOPHARMACEUTICALS INC (ABPI)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
07/15/2013 |
8-K
| Quarterly results |
03/07/2013 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
02/22/2013 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
11/23/2012 |
8-K
| Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran... |
10/15/2012 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
08/14/2012 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs:
|
"For further information, please visit: http://www.biovest.com Forward-Looking Statements: Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, statements about Biovest and its product candidate, BiovaxID™ and any other statements relating to products, product candidates, product development programs, the FDA, the EMA, Health Canada or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as “may,” “could,” “would,” “should,” “believe..." |
|
06/21/2012 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
06/07/2012 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs:
|
"Secured Promissory Note, in the original principal amount of $1,500,000 payable by Accentia Biopharmaceuticals, Inc. to Pabeti, Inc",
"Common Stock Purchase Warrant, issued by Accentia Biopharmaceuticals, Inc. to Pabeti, Inc",
"Security Agreement, by Accentia Biopharmaceuticals, Inc. in favor of Pabeti, Inc",
"Amendment No. 1 to Plan Convertible Promissory Note, between Accentia Biopharmaceuticals, Inc. and Dennis Ryll" |
|
03/08/2012 |
8-K
| Submission of Matters to a Vote of Security Holders |
11/07/2011 |
8-K
| Form 8-K - Current report |
11/04/2011 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
09/20/2011 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
09/14/2011 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
06/24/2011 |
8-K
| Form 8-K - Current report |
06/23/2011 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
05/04/2011 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
03/15/2011 |
8-K
| Form 8-K - Current report |
01/21/2011 |
8-K
| Form 8-K - Current report |
01/06/2011 |
8-K
| Form 8-K - Current report |
12/03/2010 |
8-K
| Form 8-K - Current report |
11/23/2010 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs:
|
"Amended and Restated Articles of Incorporation of Accentia Biopharmaceuticals, Inc",
"Amended and Restated Bylaws of Accentia Biopharmaceuticals, Inc",
"Notice of Effectiveness",
"Accentia Biopharmaceuticals and its majority-owned subsidiary, Biovest International, Emerge from Chapter 11 Reorganization TAMPA, FLORIDA - November 17, 2010—Accentia Biopharmaceuticals, Inc. announced that, effective today, the Company and its majority-owned subsidiary, Biovest International, Inc. have both successfully completed their reorganizations, pursuant to the respective Plans of Reorganization approved by the bankruptcy court. According to Samuel S. Duffey who serves as President & General Counsel for both Accentia and Biovest, “Today marks an exciting new beginning for Accentia and Biovest, as both companies have emerged as much stronger, more financially secure organizations. As such, we are preparing to report significant new milestones that we believe will reflect the enormo..." |
|
11/02/2010 |
8-K
| Form 8-K - Current report |
10/25/2010 |
8-K
| Filed a monthly operating report
Docs:
|
"Biovest Announces $7 Million Financing Required to Exit from Reorganization and Advance Key Regulatory and Commercial Strategies for BiovaxID ® Cancer Vaccine TAMPA, FL and MINNEAPOLIS, MN - October 25, 2010 - Biovest International, Inc. today announced that the Company has entered into definitive loan documents and other agreements for the issuance of $7 million of convertible debtor-in-possession term notes and common stock purchase warrants to institutional investors. ROTH Capital Partners, LLC acted as the exclusive placement agent. The closing occurred on October 19 th , 2010, subject to the Court entering a final order approving the transaction. On October 25, 2010, the Court entered a Final Order approving this financing transaction. Biovest intends to use the proceeds from the DIP ...",
"Monthly Operating Report of Accentia Biopharmaceuticals, Inc. for the period September 1, 2010 through September 30, 2010 filed in the United States Bankruptcy Court Middle District of Florida Case No. 8:08-bk-17795-KRM Document No. 1396" |
|
09/24/2010 |
8-K
| Form 8-K - Current report |
08/20/2010 |
8-K
| Form 8-K - Current report |
07/26/2010 |
8-K
| Form 8-K - Current report |
06/25/2010 |
8-K
| Filed a monthly operating report |
06/01/2010 |
8-K
| Form 8-K - Current report |
05/26/2010 |
8-K
| Filed a monthly operating report |
04/26/2010 |
8-K
| Filed a monthly operating report |
03/23/2010 |
8-K
| Form 8-K - Current report |
02/22/2010 |
8-K
| Form 8-K - Current report |
01/20/2010 |
8-K
| Form 8-K - Current report |
12/22/2009 |
8-K
| Filed a monthly operating report |
|
|
|